On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. As of January 28, 2025, the average one-year ...

CRISPR Therapeutics CRSP reported fourth-quarter 2024 loss of 44 cents per share, narrower than the Zacks Consensus Estimate of a loss of $1.15. In the year-ago period, the company recorded ...

CRISPR Therapeutics AG (CRSP ... At the same time, the Dow added 0.38%, and the tech-heavy Nasdaq gained 0.98%. The company's shares have seen an increase of 0.05% over the last month, not ...

In the latest trading session, CRISPR Therapeutics AG (CRSP ... and the technology-centric Nasdaq increased by 1.35%. Prior to today's trading, shares of the company had lost 5.73% over the ...

In trading on Friday, shares of CRISPR Therapeutics AG (Symbol: CRSP) crossed above their 200 day moving average of $49.55, changing hands as high as $52.60 per share. CRISPR Therapeutics AG ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago.

The Company expects to provide an update in 2025. About the CRISPR Collaboration and Vertex CRISPR Therapeutics and Vertex entered into a strategic research collaboration in 2015 focused on the ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (BRSE:1CG) from In-Line to Outperform. There are 577 funds or institutions reporting ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...